Close Menu

NEW YORK – Bristol Myers Squibb (BMS) yesterday announced that the US Food and Drug Administration (FDA) has approved the combination of the immune checkpoint inhibitor drugs nivolumab (Opdivo) and ipilimumab (Yervoy) together with two cycles of platinum-doublet chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer. The treatment combination was approved for patients without EGFR or ALK gene mutations regardless of their PD-L1 status.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.